SELLAS Life Sciences (SLS) Equity Average (2011 - 2026)

SELLAS Life Sciences (SLS) has 16 years of Equity Average data on file, last reported at $89.1 million in Q1 2026.

• Equity Average for Q1 2026 came in at $89.1 million, up 378.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $89.1 million (up 378.95% YoY), and the FY2025 annual result was $40.2 million, up 5295.3% from the prior year.
• Equity Average improved to $89.1 million in Q1 2026 per SLS's latest filing, from $58.3 million in the prior quarter.
• Over five years, Equity Average peaked at $89.1 million in Q1 2026 and troughed at -$5.9 million in Q4 2023.
• A 5-year average of $18.8 million and a median of $11.5 million in 2022 frame the typical range for Equity Average.
• The sharpest annual moves came in 2023 and 2025: Equity Average slumped 167.65% in 2023, then jumped 2079.39% in 2025.
• A 5-year view of Equity Average shows it stood at $8.7 million in 2022, then tumbled by 167.65% to -$5.9 million in 2023, then soared by 314.84% to $12.7 million in 2024, then surged by 359.44% to $58.3 million in 2025, then soared by 53.03% to $89.1 million in 2026.
• Business Quant data shows SLS's Equity Average at $89.1 million in Q1 2026, $58.3 million in Q4 2025, and $35.9 million in Q3 2025.